Jazz received US approval of Ziihera as a first-line treatment of all HER2-positive advanced gastroesophageal adenocarcinoma, or GEA, used in addition to chemotherapy, with or without Tevimbra. Additional phase 3 data further reinforced its survival advantage over Herceptin with longer follow-up.
The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age.
Jazz will face branded competition from Wakix and Lumryz, in addition to generic pressure, which will likely erode Jazz's patient share.
|
Metric
|
JAZZ
|
IONS
|
UCB
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.11 | — | 17.62 |
Price/Book Value | 3.33 | 21.88 | 3.45 |
Price/Sales | 3.45 | 10.84 | 4.79 |
Price/Cash Flow | 9.29 | — | 16.79 |
|
Metric
|
JAZZ
|
IONS
|
UCB
|
|---|---|---|---|
Quick Ratio | 1.38 | 6.70 | 0.82 |
Current Ratio | 1.78 | 7.89 | 1.20 |
Interest Coverage | 5.26 | −5.82 | 27.73 |
|
Metric
|
JAZZ
|
IONS
|
UCB
|
|---|---|---|---|
Return on Assets (Normalized) | 16.01% | −12.57% | 13.57% |
Return on Equity (Normalized) | 42.74% | −75.28% | 23.59% |
Return on Invested Capital (Normalized) | 20.79% | −14.91% | 19.03% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|FKdLHY | LOCK|M!P$ | $138B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?k^!$LL | LOCK|M&J& | $85B | |||
| argenx SE ADR
ARGX
| LOCK|?dqSXk | LOCK|GRd | $65B | |||
| Moderna Inc
MRNA
| LOCK|!n!hbS | LOCK|^X | $58B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bnM^HtG | LOCK|x# | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$f?J&r | LOCK|lYgX | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@F<^ygP | LOCK|P^!w | $28B | |||
| BioNTech SE ADR
BNTX
| LOCK|?c&<#Y | LOCK|&l! | $26B | |||
| Incyte Corp
INCY
| LOCK|z!@<McX | LOCK|@#z | $26B |
United States